Mineralocorticoid Receptor Antagonists in End Stage Renal Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

February 14, 2017

Study Completion Date

March 28, 2018

Conditions

End Stage Renal Disease / Hemodialysis

Interventions

DRUG

Spironolactone

50mg once daily

DRUG

Placebo

Trial Locations (3)

University Hospital Frankfurt, Frankfurt

University Hospital Erlangen-Nürnberg, Erlangen

University Hospital Wuerzburg, Würzburg

All Listed Sponsors

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

Clinical Trial Center Wuerzburg (CTCW)

UNKNOWN

lead

Wuerzburg University Hospital

OTHER

NCT01691053 - Mineralocorticoid Receptor Antagonists in End Stage Renal Disease | Biotech Hunter | Biotech Hunter